Home > Boards > US Listed > Biotechs > Halozyme Therapeutics (HALO)

HALO Announces First Clinical Dosing In argenx's Phase

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Fred Kadiddlehopper Member Profile
 
Followed By 24
Posts 3,477
Boards Moderated 1
Alias Born 09/22/06
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/14/2019 6:08:17 AM
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 PR Newswire (US) - 11/13/2019 10:57:00 PM
Bernadette Connaughton Appointed to Syneos Health Board of Directors GlobeNewswire Inc. - 11/12/2019 4:30:00 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/12/2019 4:29:13 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2019 4:25:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:16:44 PM
Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024 PR Newswire (US) - 11/12/2019 4:10:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:07:53 PM
Halozyme Reports Third Quarter 2019 Results PR Newswire (US) - 11/12/2019 4:01:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 11/5/2019 4:54:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 4:37:13 PM
Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint PR Newswire (US) - 11/4/2019 7:00:00 AM
Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology PR Newswire (US) - 11/4/2019 7:00:00 AM
Halozyme To Host Third Quarter 2019 Financial Results Webcast And Conference Call PR Newswire (US) - 10/21/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/1/2019 7:11:11 PM
Halozyme To Participate In 2019 Cantor Global Healthcare Conference PR Newswire (US) - 9/23/2019 8:00:00 AM
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Usi... PR Newswire (US) - 9/13/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 11:21:22 AM
Halozyme To Participate In 2019 Wells Fargo Healthcare Conference PR Newswire (US) - 8/26/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:19:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2019 4:13:31 PM
Halozyme Reports Second Quarter 2019 Results PR Newswire (US) - 8/6/2019 4:01:00 PM
Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference PR Newswire (US) - 7/25/2019 8:00:00 AM
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call PR Newswire (US) - 7/23/2019 4:01:00 PM
J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma Dow Jones News - 7/19/2019 7:45:00 AM
Fred Kadiddlehopper   Wednesday, 07/17/19 09:32:00 AM
Re: None
Post # of 5760 
HALO Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE®

Wednesday 17 July 2019

SAN DIEGO, July 17, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of efgartigimod (ARGX-113), using Halozyme's proprietary ENHANZE® drug delivery technology.

"Since the signing of our collaboration with argenx earlier this year, we have made strong progress and I am delighted that the first phase 1 trial has been initiated in such a short amount of time," said Dr. Helen Torley, President and CEO of Halozyme. "We look forward to expanding our work with argenx to bring the potential benefits of subcutaneous administration to more patients suffering from severe autoimmune diseases through our ENHANZE® technology."

Initiation of this study triggers a $5 million milestone payment to Halozyme during the current quarter under the global collaboration and license agreement between the two companies.

The more you know, the less you don't know.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist